Abstract
Post-authorization observational studies play a key role in understanding COVID-19 vaccine effectiveness following the demonstration of efficacy in clinical trials. While bias due to confounding, selection bias, and misclassification can be mitigated through careful study design, unmeasured confounding is likely to remain in these observational studies. Phase III trials of COVID-19 vaccines have shown that protection from vaccination does not occur immediately, meaning that COVID-19 risk should be similar in recently vaccinated and unvaccinated individuals, in the absence of confounding or other bias. Several studies have used the estimated effectiveness among recently vaccinated individuals as a negative control exposure to detect bias in vaccine effectiveness estimates. In this paper we introduce a theoretical framework to describe the interpretation of such a bias-indicator in test-negative studies, and outline assumptions that would allow the use of recently vaccinated individuals to correct bias due to unmeasured confounding.
Competing Interest Statement
J.A.L. has received grants and consulting fees from Pfizer, Inc., unrelated to this research. The remaining authors report no conflicts of interest.
Funding Statement
This work was supported by grants R01-AI14812701 from the National Institute for Allergy and Infectious Diseases to J.A.L., and R01-AI139761 from the National Institute for Allergy and Infectious Diseases to N.E.D.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: J.A.L. has received grants and consulting fees from Pfizer, Inc., unrelated to this research. The remaining authors report no conflicts of interest.
Source of financial support: This work was supported by grants R01-AI14812701 from the National Institute for Allergy and Infectious Diseases to J.A.L., and R01-AI139761 from the National Institute for Allergy and Infectious Diseases to N.E.D.
Code for replication is available from the corresponding author via https://github.com/mhitchings/tnccbias
Data Availability
Code for replication is available from the corresponding author via https://github.com/mhitchings/tnccbias
